2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC deficiency, ...

WARREN, NJ, USA I November 13, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of ...

PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...

Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ...

Zoom Video (NASDAQ:ZM) shares rose fractionally in premarket trading on Wednesday as Morgan Stanley upped its price target on ...

Constellation Energy Corporation stock has been volatile due to regulatory concerns, but power demand is growing. Click here ...

Joseph Schwartz, an analyst from Leerink Partners, reiterated the Hold rating on PTC Therapeutics (PTCT – Research Report). The ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $43 from $31 and keeps an Equal Weight rating on the shares. The ...

In a report released on November 8, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a ...

Charting, Price Performance, News & Related Contracts.

Q3 2024 Earnings Call Transcript November 8, 2024 Operator: Good morning, and welcome to the Calumet, Inc., Conference Call.

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...